Sequenom should be bought following solid Q2, says Maxim Maxim raised its price target for Sequenom shares to $7 from $6 and recommends buying the stock following the company's "solid" Q2 results. Maxim expects Sequenom to regain its leadership position after the firm's channel checks in Q2 indicated Ariosa's U.S. volume may have surpassed Sequenom for the first time in Q2. It keeps a Buy rating on the stock.
Sequenom genetic test false positive highlighted in NBC Nightly News report Recent studies have "cast doubt" on the reliability of pre-natal genetic tests such as Sequenom's MaterniT21 test, according to a report aired by NBC Nightly News. Reference Link